Harvard Bioscience (NASDAQ:HBIO) Price Target Lowered to $4.50 at Benchmark

Harvard Bioscience (NASDAQ:HBIO) had its price objective dropped by investment analysts at Benchmark from $5.50 to $4.50 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “speculative buy” rating on the medical instruments supplier’s stock.

Harvard Bioscience Stock Performance

NASDAQ HBIO opened at $0.66 on Monday. The firm’s fifty day moving average price is $1.28 and its two-hundred day moving average price is $1.98. The stock has a market cap of $29.00 million, a PE ratio of -1.97 and a beta of 1.46. Harvard Bioscience has a fifty-two week low of $0.60 and a fifty-two week high of $4.70. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06.

Institutional Trading of Harvard Bioscience

Several institutional investors have recently modified their holdings of the business. Jacobs Levy Equity Management Inc. bought a new stake in shares of Harvard Bioscience in the fourth quarter worth $137,000. Focus Partners Wealth bought a new stake in shares of Harvard Bioscience in the fourth quarter worth $28,000. Bank of America Corp DE grew its stake in shares of Harvard Bioscience by 44.4% in the fourth quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after purchasing an additional 11,948 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Harvard Bioscience by 55.5% in the fourth quarter. Jane Street Group LLC now owns 35,769 shares of the medical instruments supplier’s stock worth $75,000 after purchasing an additional 12,767 shares during the last quarter. Finally, Gamco Investors INC. ET AL bought a new stake in shares of Harvard Bioscience in the fourth quarter worth $200,000. Institutional investors own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.